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Abstract
Background: A new simple technique based on iontophoresis technology (EZSCAN, Impeto Medical, Paris, France)
has recently been developed for the screening of diabetes. In the present study, we investigated the accuracy of
this system for the diagnosis of diabetes mellitus in Chinese.
Methods: We performed the EZSCAN test in diabetic and non-diabetic subjects. EZSCAN measures electrochemical
conductance (EC) at forehead, hands and feet, and derives a diabetes index with a value ranging from 0 to 100.
Diabetes mellitus was defined as a plasma glucose concentration of at least 7 mmol/l at fasting or 11.1 mmol/l at
2 hours after glucose load, or as the use of antidiabetic drugs.
Results: The 195 study participants (51% men, mean age 52 years) included 75 diabetic patients (use of
antidiabetic drugs 81%) and 120 non-diabetic subjects. EC (micro Siemens, μSi) was significantly (P < 0.001) lower
in diabetic patients at the hands (44 vs. 61) and feet (51 vs. 69) locations, but not at the forehead (15 vs. 17, P =
0.39). When a diabetes index of 40 (suggested by the manufacturer) was used as the threshold, the sensitivity and
specificity for the diagnosis of diabetes mellitus was 85% and 64%, respectively. In 80 patients who underwent an
oral glucose tolerance test, EC at hands and feet and the diabetes index were significantly (P < 0.001) associated
with both 2-hour post-load plasma glucose and serum glycosylated haemoglobin.
Conclusions: EZSCAN might be useful in screening diabetes mellitus with reasonable sensitivity and specificity.
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Background
The prevalence of type 2 diabetes mellitus is high in
most countries. According to the most recent nation-
wide survey in China, the prevalence of diabetes mellitus
and impaired glucose metabolism was 9.7% and 15.5%,
respectively [1]. While diabetes mellitus is becoming a
major public health problem, the identification of this
disease is still difficult [2]. The oral glucose tolerance
test (OGTT) is complicated. The measurement of glyco-
sylated haemoglobin (HbA1c) requires high cost, and
has low sensitivity, and no fully standardized analytical
method. The fasting blood glucose measurement either
via venous or capillary sampling is currently used for
screening, but is not sufficiently sensitive. Indeed, if fast-
ing blood glucose was used solely in the diagnosis of
diabetes mellitus, the sensitivity was as low as 40% [3].
The recently developed EZSCAN system employs a
novel technology of reverse iontophoresis [4] and mea-
sures function of sweat glands as a parameter of small
nerve fiber dysfunction that may present early in predia-
betes [5,6]. The original measurement of the system is
sweat chloride concentration, while administering a low-
voltage electric current at the feet, hands and forehead.
With an algorithm accounting for sex, age, body mass
index, and systolic blood pressure, an index could be
derived for the diagnosis of diabetes mellitus, impaired
glucose metabolism, and diabetic neuropathy. The system
has been tested in Europe [7] and India [8] for the diag-
nostic accuracy of diabetes mellitus. In the present
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derived diabetes index in the diagnosis of diabetes melli-
tus, and then correlated this index and the original electro-
chemical conductance measurement with concentrations
of 2-hour post-load plasma glucose and serum HbA1c.
Methods
Study subjects
The study participants (n = 195) were recruited from
known diabetic patients enrolled in a trial of self blood
glucose monitoring (n = 54), from hypertensive patients
hospitalized in the Department of Hypertension, Ruijin
Hospital (Shanghai, China, n = 96), and from apparently
healthy volunteers (n = 45). We performed the EZSCAN
test in all these participants. In the 96 hospitalized hyper-
tensive patients, we also performed OGTT and measured
serum HbA1c concentration in those who had no history
of diabetes mellitus (n = 80) after exclusion of 12 patients
with known diabetes mellitus and 4 patients who
declined to participate. The Ethnics Committee of Ruijin
Hospital, Shanghai Jiaotong University School of Medi-
cine (Shanghai, China) approved the study protocol. All
subjects gave written informed consent.
The EZSCAN test
The EZSCAN system is designed to evaluate sweat-gland
function by measuring sweat chloride concentrations
using reverse iontophoresis and chronoamperometry. Two
sets of large-area nickel electrodes are used as anode and
cathode. A direct current at an incremental voltage of 4 V
or less is applied to the anode. This applied current gener-
ates voltage to the cathode and a current between the
anode and cathode. This generated current is proportional
to chloride concentration and measurable by chronoam-
perometry. The electrochemical conductance (μSi) is cal-
culated as the ratio of the current measured over the
constant power applied for the forehead (left and right
parts), hands (left and right), and feet (left and right) and
for the whole body. A diabetes index is then derived from
these electrochemical conductance measurements with an
algorithm accounting for sex, age, body mass index, and
systolic blood pressure, for the classification of glucose
metabolism as the presence (diabetes index ≥40) or
absence of diabetes mellitus (diabetes index < 40).
A trained physician (CSS) performed the EZSCAN test,
after he administered a questionnaire to collect informa-
tion on medical history and the use of medications, and
measured body weight and body height. Blood pressure
was measured three times consecutively after the subjects
had rested for at least 5 minutes in the sitting position.
These three blood pressure readings were averaged for
analysis. Before the EZSCAN test, the operator had to
enter the following variables into the system: sex, age,
body height, body weight, and systolic blood pressure,
but the subject did not require for any preparation, such
as fasting or no vigorous exercise. During the 2-min test,
the subject was asked to stand up still with the hands and
feet on the pads of electrode and with the headband on
the forehead.
OGTT and laboratory methods
A standard OGTT was performed after overnight fasting
of 8-10 h according to the WHO recommendations [9]
in subjects without known diabetes mellitus. Blood sam-
ples were drawn immediately and 30, 60, 120, and 180
minutes after an oral load of 75 g anhydrous glucose.
Plasma glucose was measured by the glucose oxidase
peroxidase method. Diabetes mellitus was defined as a
plasma glucose of at least 7.0 mmol/L fasting or 11.1
mmol/L at 2 hours after glucose load, or as the use of
antidiabetic agents [9]. HbA1c was measured by the
HPLC method [10].
Statistical methods
For database management and statistical analysis, we
used SAS software (version 9.13, SAS Institute, Cary, NC,
USA). Means and proportions were compared with the
Student’s t-test and Fisher’s exact test, respectively. The
Receiver Operating Characteristic (ROC) [11] curve was
used to show sensitivity and specificity of the EZSCAN
diabetes index for the diagnosis of diabetes mellitus. We
calculated Pearson correlation coefficients to test the cor-
relations of the original electrochemical conductance
measurements and the derived diabetes index with con-
centrations of 2-hour post-load plasma glucose and
serum HbA1c.
Results
195 participants included 99 (51%) men and 75 (39%)
diabetic patients, of whom 61 (81%) took antidiabetic
medication. Diabetic patients, compared with non-dia-
betic subjects, were older (+14 years, P < 0.0001), and
had a greater body mass index (+2 kg/m
2, P = 0.0001)
and higher systolic blood pressure (+9 mmHg, P =
0.003) and fasting plasma glucose (+2 mmol/L, Table 1).
Diabetic patients, compared with non-diabetic sub-
jects, had significantly (P < 0.0001) lower electrochemi-
cal conductance for the hands (44 vs. 61 μSi), feet (51
vs. 69 μSi), and the whole body (37 vs. 49 μSi) but not
for the forehead (15 vs. 17 μSi, P = 0.39), and had signif-
icantly (P < 0.0001) higher EZSCAN diabetes index (67
vs. 35, Table 2).
The ROC curve shows the diagnostic accuracy of the
derived EZSCAN diabetes index for the diagnosis of dia-
betes mellitus (Figure 1). The area under the curve (AUC)
was 80% of the total square. If the EZSCAN diabetes index
of 40 was used as the threshold for the diagnosis of dia-
betes mellitus in all subjects, the sensitivity and specificity
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to 50 and 60, the diagnostic sensitivity dropped to 67%
and 60%, respectively, and the diagnostic specificity rose to
72% and 78%, respectively (Table 3). In 80 patients who
had no history of diabetes mellitus and had an OGTT, 9
(11.3%) were diagnosed as diabetes mellitus by OGTT. In
these patients, the EZSCAN diabetes index of 40 had
higher sensitivity (78%) than fasting plasma glucose (44%)
or serum HbA1c (56%, Table 3).
After stratification for sex and age (below or above the
median of 54 years), we calculated sensitivity and speci-
ficity of the diabetes index of 40 in men (n = 99) and
women (n = 96) and in the younger (n = 100) and older
(n = 95) subjects. The EZSCAN system had similar sen-
sitivity and specificity in both sexes (P≥0.50), but tended
to have higher sensitivity and lower specificity in older
than younger subjects (P≤0.003, Table 3).
In further analysis, we correlated the original electroche-
mical conductance measurement and the derived EZS-
CAN diabetes index with concentrations of 2-hour post-
load plasma glucose and serum HbA1c in 80 patients who
had an OGTT. The electrochemical conductance was sig-
nificantly (P≤0.009) and negatively correlated with both 2-
hour post-load plasma glucose concentration and serum
HbA1c at the hands (r = -0.35 and r = -0.35, respectively)
and feet (r = -0.29 and r = -0.38, respectively) but not (P≥
0.53) at the forehead (r = -0.02 and r = 0.07, respectively,
Figure 2). The EZSCAN diabetes index was significantly
(P≤0.004) correlated with 2-hour post-load glucose (r =
0.32) and HbA1C (r = 0.38, Figure 3).
Discussion
Our study demonstrated that EZSCAN, as a screening
tool, had an acceptable accuracy for the diagnosis of dia-
betes mellitus. Indeed, if a diabetes index of 40 would be
used as the threshold, the diagnostic sensitivity and spe-
cificity was 85% and 64%, respectively. In addition, the
electrochemical conductance at the hands and feet but
not at the forehead was significantly associated with 2-
hour post-load plasma glucose concentration and serum
HbA1C concentration.
To the best of our knowledge, only 2 published stu-
dies investigated the accuracy of EZSCAN for the diag-
nosis of impaired glucose metabolism. In 212 subjects
recruited in India [7], EZSCAN, when a diabetes index
of 50 was used as the threshold, had a sensitivity of 75%
f o rt h ed i a g n o s i so fd i a b e t e sm e l l i t u s( n=2 4 ) ,a n da
specificity of 54% in patients with normal glucose toler-
ance and without the metabolic syndrome (n = 101).
The corresponding sensitivity and specificity for fasting
Table 1 Characteristics of the study participants
Characteristic Diabetic patients*
(n = 75)
Non-diabetic subjects
(n = 120)
P value
Men, n (%) 34 (45.3) 65 (54.2) 0.23
Age, years 60.5 ± 8.4 47.0 ± 16.2 < 0.0001
Body height, cm 162.7 ± 9.3 166.4 ± 9.1 0.006
Body weight, kg 70.4 ± 12.7 68.3 ± 12.9 0.26
Body mass index, kg/m
2 26.6 ± 3.9 24.5 ± 3.3 0.0001
Systolic blood pressure, mm Hg 143.5 ± 14.2 136.4 ± 18.5 0.003
Diastolic blood pressure, mm Hg 80.2 ± 9.2 81.8 ± 10.2 0.50
Fasting blood glucose, mmol/L 6.86 ± 1.23 5.07 ± 0.59 < 0.0001
Use of anti-diabetic drugs, n (%) 61 (81.3%) 0 -
Values are mean ± standard deviation, or number of subjects (%).
*Diabetes mellitus was defined as a plasma glucose of at least 7.0 mmol/L fasting or 11.1 mmol/L at 2 hours post-load, or as the use of antidiabetic agents.
Table 2 The electrochemical conductance and the EZSCAN diabetes index in diabetic and non-diabetic subjects
Diabetic patients*
(n = 75)
Non-diabetic subjects
(n = 120)
Relative difference
(95% confidence interval)
P value
Electrochemical conductance, μSi
Feet 50.9 ± 21.9 69.1 ± 16.8 -26.3% (-18.4–34.3%) < 0.0001
Hands 43.7 ± 20.4 61.2 ± 15.5 -28.6% (-20.3–36.9%) < 0.0001
Forehead 15.1 ± 17.8 17.4 ± 18.8 -13.2% (-44.3-17.8%) 0.39
Overall 36.6 ± 15.8 49.2 ± 11.8 -25.8% (-17.7–33.7%) < 0.0001
EZSCAN diabetes index (0-100)
Mean ± SD 66.6 ± 25.8 34.6 ± 27.9 92.5% (70.0-115.6%) < 0.0001
Median (inter-quartile range) 68 (48) 29 (47) - < 0.0001
Values are mean ± standard deviation, unless otherwise indicated.
*Diabetes mellitus was defined as a plasma glucose of at least 7.0 mmol/L fasting or 11.1 mmol/L at 2-hour post-load, or as the use of antidiabetic agents.
Sheng et al. Diabetology & Metabolic Syndrome 2011, 3:36
http://www.dmsjournal.com/content/3/1/36
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respectively. In Indians, EZSCAN apparently had higher
sensitivity but lower specificity than fasting glucose. In
133 diabetic patients and 41 healthy volunteers recruited
in France [8], EZSCAN had a sensitivity of 75% and a
specificity of 100%.
Figure 1 Accuracy of EZSCAN for the diagnosis of diabetes mellitus, analyzed by Receiver Operating Characteristic (ROC) curve.
Table 3 Sensitivity and specificity for the diagnosis of diabetes mellitus
Sensitivity (%) Specificity (%)
EZSCAN in all subjects (n = 195)*
EZSCAN diabetes index ≥ 40 85 64
EZSCAN diabetes index ≥ 50 67 72
EZSCAN diabetes index ≥ 60 60 78
EZSCAN in subgroup analysis (diabetes index ≥40 as threshold)
Men (n = 99) 82 65
Women (n = 96) 87 63
< 54 years (median age, n = 100) 61 83
≥54 years (median age, n = 95) 93 24
Comparison of 3 methods in patients who had an oral glucose tolerance test (n = 80)*
EZSCAN diabetes index ≥ 40 78 67
Fasting plasma glucose ≥ 7.0 mmol/L 44 100
Serum glycosylated haemoglobin ≥ 6.5% 56 93
*Diabetes mellitus was defined as a plasma glucose of at least 7.0 mmol/L fasting or 11.1 mmol/L at 2 hours post-load, or as the use of antidiabetic agents in all
subjects (75 diabetic patients), and as a plasma glucose of at least 7.0 mmol/L fasting or 11.1 mmol/L at 2 hours post-load in patients who had an oral glucose
tolerance test (9 diabetic patients).
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research together, EZSCAN seemed to have consistent
and constant sensitivity (75% in Indians and French and
85% in Chinese) but divergent and variable specificity
(54%, 100%, and 64%, respectively) across populations.
The heterogeneous specificity might be attributable to
the differences in characteristics of participants between
these 3 studies, because subjects who had any risk factor
Figure 2 Scatter plots with regression line for the relation of the electrochemical conductance at the hands (circles), feet (triangles)
and forehead (squares) locations with 2-hour post-load plasma glucose concentration (left panel) and serum glycosylated
haemoglobin (HbA1c, right panel) in patients who had an oral glucose tolerance test (n = 80). The dashed vertical line denotes the
threshold for the diagnosis of diabetes mellitus. Open and closed symbols represent diabetic patients and non-diabetic subjects, respectively.
Correlation coefficients and P values are given for the feet, hands and forehead locations separately.
Figure 3 Scatter plots with regression line for the relation of the EZSCAN diabetes index with 2-hour post-load plasma glucose
concentration (left panel) and serum glycosylated haemoglobin (HbA1c, right panel) in patients who had an oral glucose tolerance
test (n = 80). For further information, see legend to Figure 2.
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activity, and first-degree relative with diabetes) were
excluded from the non-diabetic control group of the
French study [8] but not the Indian [7] and our Chinese
studies. Nonetheless, it is also possible that the algo-
rithm for the computation of the diabetes index and the
cutoff value for the diagnosis of diabetes mellitus gener-
ated from the French population cannot directly be gen-
eralized to populations of other ethnicities.
Despite different diagnostic accuracy across popula-
tions, EZSCAN does measure something that reflects or
is related to glucose metabolism. The original electro-
chemical conductance measurement at hands and feet
was different between diabetic and non-diabetic subjects,
and associated with 2-hour post-load plasma glucose
and with serum HbA1c. The EZSCAN diabetes index
was also associated with 2-hour post load plasma glu-
cose and serum HbA1c.
Our finding that the electrochemical conductance was
significantly different between diabetic and non-diabetic
subjects only at the feet and hands locations but not at
forehead are in keeping with the results of the French
study [8], and might have important implications for
future upgrading of the EZSCAN system. In the French
study, diabetic patients, compared with non-diabetic
subjects, had a lower electrochemical conductance at
the feet and hands locations but an even higher value at
forehead [8]. The electrochemical conductance measures
function of sweat glands and activity of the correspond-
ing autonomic nerves that are longest at the feet, inter-
mediate at the hands, and shortest at the forehead [12].
We speculate that longer nerves are more susceptible
for neuropathic lesions, regardless as a complication or
in reverse as a cause of diabetic mellitus [13-15]. Thus,
only the electrochemical conductance at the feet and
hands locations is sufficiently sensitive to identify the
presence of diabetes mellitus, and should be used in the
upgraded system.
One of the major strengths of our study was that we
performed OGTT and measured HbA1c, and compared
the accuracy of the EZSCAN system with that of fasting
plasma glucose and HbA1c. Nonetheless, our study had
a small sample size and a cross-sectional design. A lar-
ger prospective study is apparently required.
In conclusion, EZSCAN is accurate in the diagnosis of
diabetes mellitus with reasonable sensitivity and specifi-
city as a screening tool. With the increasing use and
knowledge, EZSCAN might bring revolutionized
changes to the identification of diabetes mellitus as a
screening tool and also to the understanding of mechan-
isms of blood glucose regulation as a research tool.
More research is apparently required to investigate the
significance of EZSCAN for risk stratification and pre-
diction of cardiovascular and renal events in prospective
studies, and to explore the role of EZSCAN in therapeu-
tic monitoring of diabetes mellitus in controlled clinical
trials. Before the evidence is becoming available, this
system should be recommended for the use in the
research setting.
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